LY3039478 + abemaciclib

This is an investigational **oral small-molecule combination** regimen consisting of **LY3039478** and **abemaciclib**. LY3039478, also known as a gamma secretase inhibitor, targets the **Notch signaling pathway**, which is implicated in tumorigenesis by affecting cell fate determination and survival. **Abemaciclib** is a **selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6)**, thereby impairing cell cycle progression through the G1 phase and inhibiting cancer cell proliferation. The combination has been studied in advanced or metastatic solid tumors, especially in those malignancies with **Notch pathway alterations**. The combination was evaluated primarily for safety, pharmacokinetics, and preliminary antitumor efficacy in a **Phase 1 trial** sponsored by Eli Lilly and Company.